Full text is available at the source.
Abstract
Diabetic peripheral neuropathy is a debilitating complication of type 2 diabetes mellitus (T2DM).
- Diabetic peripheral neuropathy is linked to serious outcomes, including foot ulcers and amputations.
- The use of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in T2DM treatment raises questions about their effects on neuropathy-related complications.
- Comparative effects of these therapies on lower-extremity complications associated with neuropathy are not well understood.
Simplified